Home
Overview
Results of the early benefit assessment
G-BA procedures
Resolutions
Subgroups
Patients
Procedures without a dossier
Indication areas (G-BA)
Eye diseases
Skin diseases
Cardiovascular diseases
Infectious diseases
Respiratory system diseases
Hematopoietic diseases
Musculoskeletal system diseaeses
Nervous system diseases
Genitourinary system diseases
Digestive system diseases
Oncological diseases
Mental illnesses
Other diseases
Metabolic diseases
Orphan Drugs
Special marketing authorisations
Orphan drugs
PUMA
ATMP
ATMP CAR-T cells
Conditional marketing authorisation
Approval under exceptional circumstances
Accelerated assessment
Evidence transfer
Results of reassessments
Limitation
G-BA request (§13 VerfO)
Manufacturer's request (§14 VerfO)
Orphan drugs, turnover exceeding €50m
Orphan drugs, loss of status
G-BA requirements
Collection of routine practice data (AbD)
Quality requirements for ATMP
Bundling
Repealed resolutions
Procedures
G-BA resolutions
G-BA active procedures
EMA CHMP positive opinions
Arbitrations
Reimbursement prices
Recent price changes
Arbitration results
Discontinuations
Special practice conditions
Exclusions from prescription
Changes in legal regulations
Interactive Analysis
Resolutions
Subgroups
Intelligent search
Fundamentals
AMNOG Monitor step by step
Detailed analysis for each G-BA resolution
Interactive analysis
Interactive analysis: Excel export
Interactive analysis: Bookmarks
Interactive analysis: dimensions
Intelligent search
Monthly report
AMNOG Monitor app
Calculation methods
Changes in legal regulations
EMA regulatory procedure
Arbitration board
Endpoints Quality of Life
Technical terms English-German
Contact
Contact form
Legal notice
Privacy policy
Search G-BA resolutions
Login:
Login
Username
Password
Orphan drugs
PUMA
ATMP
ATMP CAR-T cells
Conditional marketing authorisation
Approval under exceptional circumstances
Accelerated assessment
Evidence transfer
Log in to read more ...
The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.
Login
Username
Password
